TrialNeuro-oncology2024
Final outcome analysis from the phase II TUXEDO-1 trial of trastuzumab-deruxtecan in HER2-positive breast cancer patients with active brain metastases.
Rupert Bartsch et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
49 papers cite it
this paperpooled ittrialcites it